Disparities in the treatment of cardiogenic shock: does sex matter?

Amy S Wang1, Samantha Nemeth2, Alice Vinogradsky1

  • 1Department of Surgery, Division of Cardiothoracic and Vascular Surgery, Columbia University Medical Center, New York, NY, USA.

Insights

This study found no difference in survival for male and female patients undergoing venoarterial extracorporeal life support (VA-ECLS) for cardiogenic shock. However, female patients experienced more limb ischemia complications.

Area of Science:

  • Cardiology
  • Critical Care Medicine
  • Medical Technology

Background:

  • Extracorporeal life support (ECLS) use for cardiogenic shock has risen.
  • Limited data exist on sex-based outcome disparities in VA-ECLS.
  • This study addresses sex-associated outcomes in VA-ECLS for cardiogenic shock.

Purpose of the Study:

  • To assess sex-based differences in outcomes for patients on VA-ECLS for cardiogenic shock.
  • To analyze mortality and complication rates between male and female patients.

Main Methods:

  • Retrospective analysis of 9888 adult patients from the ELSO registry (2011-2019).
  • 1:1 nearest neighbor propensity score matching was employed.
  • Primary endpoint: in-hospital mortality; Secondary endpoints: bleeding, infection, and other complications.

Main Results:

  • 68% male and 32% female patients; males had more comorbidities.
  • Post-matching, no significant difference in in-hospital mortality was observed.
  • Females had higher rates of limb ischemia; males had higher rates of renal replacement therapy and longer hospital stays.

Conclusions:

  • No in-hospital mortality difference between sexes receiving VA-ECLS for cardiogenic shock.
  • Female patients showed increased incidence of limb ischemia.
  • Further investigation into cannulation strategies for females is warranted.
Abstract

Related Concept Videos

Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
956
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
483
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
64
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
27
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19